首页> 外文OA文献 >Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor

【2h】

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor

机译：平均血小板体积和淋巴细胞到单核细胞比与EGFR-突变体激酶抑制剂治疗的EGFR-突变体肺腺癌的无进展存活率较短

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kousuke Watanabe; Atsushi Yasumoto; Yosuke Amano; Hidenori Kage; Yasushi Goto; Yutaka Yatomi; Daiya Takai; Takahide Nagase;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line [J] . Ivana Sullivan, David Planchard Frontiers in Medicine . 2016,第4期

机译：下一代EGFR酪氨酸激酶抑制剂可用于治疗EGFR突变型一线以上的肺癌
2. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma (vol 14, pg 423, 2019) [J] . Li Changhui, Zhang Bo, Guo Jindong, Targeted oncology . 2019,第4期

机译：表皮生长因子受体（EGFR） - 纯甘氨酸激酶抑制剂（TKI）与EGFR-突变体肺腺癌患者的化疗延迟脑转移联合（Vol 14，PG 423,2019）
3. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma [J] . Li Changhui, Zhang Bo, Guo Jindong, Targeted oncology . 2019,第4期

机译：表皮生长因子受体（EGFR）-TYROSINE激酶抑制剂（TKI）联合EGFR-突变肺腺癌患者的化疗延迟脑转移
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor [O] . Kousuke Watanabe, Atsushi Yasumoto, Yosuke Amano, 2012

机译：EGFR酪氨酸激酶抑制剂治疗的EGFR突变型肺腺癌的平均血小板体积和淋巴细胞/单核细胞比例与较短的无进展生存期相关
7. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line [O] . Ivana Sullivan, David Planchard 2017

机译：下一代EGFR酪氨酸激酶抑制剂用于治疗超过一线的EGFR突变肺癌

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor

著录项

引文网络

相似文献

相关主题

期刊订阅